2Xideas AG Sells 24,915 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

2Xideas AG decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 26.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 70,654 shares of the medical equipment provider's stock after selling 24,915 shares during the period. 2Xideas AG owned about 0.10% of Lantheus worth $6,321,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC bought a new stake in Lantheus during the 4th quarter worth about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the 4th quarter worth about $37,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in shares of Lantheus in the third quarter valued at about $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock worth $6,110,806. Company insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on LNTH shares. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Trading Up 2.5 %

Shares of NASDAQ:LNTH traded up $2.43 on Friday, hitting $100.94. The company had a trading volume of 251,320 shares, compared to its average volume of 952,342. The stock has a 50 day moving average price of $93.80 and a 200 day moving average price of $95.67. The stock has a market cap of $6.91 billion, a price-to-earnings ratio of 16.70 and a beta of 0.20. Lantheus Holdings, Inc. has a 1-year low of $59.56 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.